Sumitomo Dainippon Pharma Co., Ltd.
Corporate Profile
Sumitomo Dainippon Pharma Co., Ltd., operates every day to achieve its corporate mission “to broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide”. By pouring all our efforts into the research and development of new drugs, we aim to provide innovative and effective pharmaceutical solutions to people not only in Japan but also around the world in order to realize our corporate mission.

With our acquisition of Sepracor Inc. (current Sunovion Pharmaceuticals Inc.) in 2009, we have established our own sales and marketing infrastructure in the U.S. The globalization of our operations has progressed significantly by the 2011 launch of Latuda®, a key product in our global business strategy. We were also successful in gaining a strong foothold in the oncology area through the 2012 acquisition of Boston Biomedical Inc., a U.S. biotechnology venture company.

In our Third Mid-term Business Plan that began in 2013, our corporate vision is two-fold: “Aspire to be a globally active R&D-based company” and “Contribute to medical care through leading-edge technologies.” For the realization of this vision, we are redoubling efforts to promote innovations. In addition to the focused research and development areas of Psychiatry & Neurology and Oncology, we are channeling our R&D energies also into two new fields: diseases for which no approved drugs exist as well as Regenerative Medicine / Cell Therapy.

Constantly aware of our responsibility to you and all our stakeholders from patients, their families and medical caregivers to our shareholders, employees and the communities where we work, we pledge our unflagging efforts to earn and maintain your trust in us. On behalf of all of us at Sumitomo Dainippon Pharma, I would like to ask for your continued support and encouragement.
Corporate Information 1

Corporate Profile

<table>
<thead>
<tr>
<th>Name</th>
<th>Sumitomo Dainippon Pharma Co., Ltd.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Established</td>
<td>May 14, 1897</td>
</tr>
<tr>
<td>Date of merger</td>
<td>October 1, 2005</td>
</tr>
<tr>
<td>Representative</td>
<td>Masayo Tada, Representative Director, President and CEO</td>
</tr>
<tr>
<td>Capitalization</td>
<td>22.4 billion yen (as of December 31, 2017)</td>
</tr>
<tr>
<td>Fiscal year</td>
<td>April 1 to March 31</td>
</tr>
<tr>
<td>Employees</td>
<td>3,556 (6,529: consolidated) (as of December 31, 2017)</td>
</tr>
<tr>
<td>Business (consolidated)</td>
<td>Manufacturing and sales of Pharmaceuticals, food ingredients, food additives, veterinary medicines, diagnostics and others</td>
</tr>
<tr>
<td>Osaka Head office</td>
<td>6-8, Doshomachi 2-chome, Chuo-ku, Osaka, Osaka, Japan (Zip code 541-0045) Main number: +81-6-6203-5321</td>
</tr>
<tr>
<td>Tokyo Head office</td>
<td>13-1, Kyobashi 1-chome, Chuo-ku, Tokyo, Japan (Zip code 104-8356) Main number: +81-3-5159-2500</td>
</tr>
</tbody>
</table>

Brand Mark

“Green Prism”, the symbol of Sumitomo Dainippon Pharma Co., Ltd., is a motif in the design of the “Sun” — expressing a lively sense of energy, moving on toward tomorrow; “Light” — to convey the potential and hope of the future; and “Flower” — engendering the joyous and liberated sensation of basking in good health. A design crafted to embody preeminent research and development powers, a thorough support system, the spirit of challenge, and the other stances of Sumitomo Dainippon Pharma — a company bent on supplying all people with the strength to push on toward an even brighter tomorrow. Emanating from the symbol, furthermore, is the image of a network, steadily spreading out into the world. The corporate color of Green plays on the hue of fresh young leaves and other images of healthy and energetic moods, and signs of what the future holds.

Global Slogan

Innovation today, healthier tomorrows

Befitting Sumitomo Dainippon Pharma’s tenth anniversary of the merger, “Innovation today, healthier tomorrows” is the global slogan adopted by four pharmaceutical companies of Sumitomo Dainippon Pharma group (Sumitomo Dainippon Pharma, Sunovion Pharmaceuticals, Boston Biomedical, and Sumitomo Pharmaceuticals (Suzhou)). The global slogan reflects our full commitment to deliver to society revolutionary pharmaceuticals, acquired through groundbreaking ideas and high-standard research and development by each individual employee’s challenge for innovation, so as to help enable the patients and their families lead healthier and fulfilling lives.
Corporate Information 2

Corporate Mission

To broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide

Management Mission

- To contribute to healthcare and people's well-being based upon the principles of patient-oriented management and innovative research
- To continuously strive to maximize corporate value through constant business development and to fulfill shareholder expectations
- To create an environment in which employees can fulfill their potential and increase their creativity
- To maintain the trust of society and to contribute to the realization of a better global environment

Declaration of Conduct

At Sumitomo Dainippon Pharma, directors and employees alike are determined not only to comply with all laws and regulations, but also to ensure that all corporate activities are carried out in accordance with this Declaration of Conduct. The pledges below express our commitment to earning greater trust from society and becoming a truly innovative company.

1. Follow through the global slogan “Innovation today, healthier tomorrows.”
   We constantly pursue self-innovation to deliver innovative products and services with speed so that people around the world can lead healthier and more fulfilling lives.

2. Pursue trustworthy corporate activities.
   We comply with laws and regulations, and conduct transparent and fair corporate activities with a good sense of ethics. We resolutely sever all relations with antisocial forces and organizations that pose a threat to the order and security of civil society.

3. Positively disclose information and properly manage information.
   We disclose corporate information in a timely and appropriate manner. We take appropriate measures to protect and manage personal and customer information acquired through corporate activities.

4. Help employees reach their full potential.
   We respect diversity, character and personality of employees. We ensure a safe and pleasant working environment, and provide employees the opportunity to develop their skills and abilities.

5. Respect human rights.
   We respect the rights of all people associated with our company in conducting corporate activities. We do not discriminate or harass anyone. In addition, we reject child labor and forced labor.

6. Positively address global environmental issues.
   We positively initiate measures in acknowledgment of environmental issues, which are common challenges to humanity and important requirements for corporate sustainability and activities.

7. Build harmonious relationships with society.
   We engage in community involvement activities including philanthropy by communicating with all of stakeholders. We conduct business by taking into consideration the local culture and customs of the countries and regions, and contribute toward the development of the local economy and society.

Top management recognizes that it is its role to realize the spirit of this Declaration and takes the lead in an exemplary manner to implement the Declaration within the corporation and its entire corporate group, while encouraging its business counterparts to follow the same example. In case the Declaration is violated, top management should take charge to resolve the situation and make efforts to determine the cause of infringement and prevent similar violations in the future. At the same time, top management should disclose information in a timely and appropriate manner, explain what has occurred, and, upon determining the source of competence and responsibility, impose strict disciplinary action against those held responsible, including top management itself.

Sumitomo Dainippon Pharma Co., Ltd.
In October 2005, Sumitomo Dainippon Pharma Co., Ltd. was formed through the merger of Dainippon Pharmaceutical Co., Ltd. and Sumitomo Pharmaceuticals Co., Ltd. Sumitomo Dainippon Pharma aims to actualize its vision of becoming “an innovative pharmaceutical company with a strong market presence.” We are aiming for the enhancement of the domestic revenue base, promotion of the development of overseas business, enhancement of development pipelines and development as well as making aggressive investments for future growth.

<table>
<thead>
<tr>
<th>Year</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>2006</td>
<td>AmBisome® (therapeutic agent for systemic fungal infection) launched.</td>
</tr>
</tbody>
</table>
| 2007 | REPLAGAL® (therapeutic agent for Anderson-Fabry disease) launched.  
The laboratory products business was transferred to DS Pharma Biomedical Co., Ltd.  
The mid-term business plan (for the period from fiscal 2007 to fiscal 2009) started. |
| 2008 | LONASEN® (atypical antipsychotic) launched.  
AVAPRO® (therapeutic agent for hypertension) launched. |
| 2009 | TRERIEF® (therapeutic agent for Parkinson’s disease drug) launched.  
A holding company (Dainippon Sumitomo Pharma America Holdings, Inc.) established in the United States.  
Acquired Sepracor Inc. (Current Sunovion Pharmaceuticals Inc.), Sepracor (Current Sunovion Pharmaceuticals Inc.) became a wholly-owned subsidiary of U.S. holding company. |
| 2010 | MIRIPLA® (therapeutic agent for hepatocellular carcinoma) launched.  
The 2nd mid-term business plan (for the period from fiscal 2010 to fiscal 2014) started.  
Sepracor Inc. (Current Sunovion Pharmaceuticals Inc.) and Dainippon Sumitomo Pharma America, Inc. merged in the United States.  
METGLUCO® (biguanide oral hypoglycemic) launched.  
The Human Grows Hormone business transferred.  
The Animal Health Products business split off and DS Pharma Animal Health Co., Ltd. established.  
The Food & Specialty Products business integrated into its subsidiary Gokyo Trading Co., Ltd. and corporate name changed to DSP Gokyo Food & Chemical Co., Ltd.  
Sepracor Inc. changed its company name to Sunovion Pharmaceuticals Inc. |
| 2011 | LATUDA® (atypical antipsychotic) launched in the United States by Sunovion Pharmaceuticals Inc.  
SUREPOST® (rapid-acting insulin secretagogue) launched. |
| 2012 | Acquired Boston Biomedical, Inc.  
ZETONNA® (therapeutic agent for allergic rhinitis) launched in the U.S. by Sunovion Pharmaceuticals Inc.  
Sunovion Pharmaceuticals Inc. acquired Elevation Pharmaceuticals Inc. (Current SRD)  
AIMIX® (therapeutic agent for hypertension) launched. |
| 2013 | A Subsidiary (Sunovion Pharmaceuticals Asia Pacific Pte Ltd.) established in Singapore.  
The 3rd mid-term business plan (for the period from fiscal 2013 to fiscal 2017) started.  
Dainippon Sumitomo Pharma Europe Ltd. changed its company name to Sunovion Pharmaceuticals Europe Ltd.  
Joint venture company (Create Vaccine Company, Ltd.) established.  
An anti-cancer drugs sales subsidiary company (Boston Biomedical Pharma, Inc.) established in the U.S. |
Dainippon Pharmaceutical Co., Ltd., established on May 14, 1897. Twenty-one prominent leaders in the pharmaceutical industry in Doshomachi, Osaka, founded Osaka Pharmaceuticals Co., Ltd. In 1898, Pharmaceutical Plant (former, Osaka Plant and former, Osaka Center) established in Ebie, Osaka. The company acquired the semigovernmental Dainippon Pharmaceutical Company in Tokyo and changed the name of the company to Dainippon Pharmaceutical Co., Ltd.

Sumitomo Pharmaceuticals Co., Ltd., established on February 6, 1984, from the Research, Development, and Manufacturing divisions of Sumitomo Chemical Co., Ltd.’s pharmaceuticals business, as well as the Pharmaceuticals Sales division of Inabata & Co., Ltd., the sole distributor of Sumitomo Chemical Company’s pharmaceuticals. The new company opened for business on October 1.
Corporate Governance

Basic concept on corporate governance

Sumitomo Dainippon Pharma Co., Ltd. (the “Company”) has established the Basic Policy on Corporate Governance and commits itself to continuously pursuing the establishment of a corporate governance system which is highly effective, aiming for the fuller realization of our Corporate Mission and Management Mission.

Factors that could significantly influence corporate governance

Sumitomo Chemical Co., Ltd. is the parent company of Sumitomo Dainippon Pharma with a 51.13% (as of September 30, 2017) share of voting rights. Respect for autonomy is affirmed by the parent company and management independence is maintained, with no restraints on approvals or other matters by the parent company concerning Sumitomo Dainippon Pharma’s business operations.

Furthermore, no directors of Sumitomo Chemical sit on the Sumitomo Dainippon Pharma Board of Directors. Sumitomo Dainippon Pharma retains some personnel seconded from the parent company based on Sumitomo Dainippon Pharma’s own judgment, and believes this has no influence on Sumitomo Dainippon Pharma’s management or business operations. Respect for autonomy is affirmed by the parent company and Sumitomo Dainippon Pharma’s independence is maintained. Based on the above, Sumitomo Dainippon Pharma believes that the interests of its retail shareholders are not impaired by its parent company.

Management structure

The Company has elected the organizational structure of a “Company with an Audit & Supervisory Board” and has appointed Independent Outside Directors to audit the execution of duties by the Directors, independent of the Board of Directors. In addition, the Company has adopted an executive officer system to separate management supervision from business execution.

The Board of Directors consists of eight members, including three Independent Outside Directors. The Board of Directors holds a meeting once a month, in principle, and resolves and reports on material business matters.

The Audit & Supervisory Board consists of five members, including three Outside Audit & Supervisory Board Members. The Audit & Supervisory Board holds a meeting once a month, in principle, discusses and resolves material matters relating to auditing, and also examines in advance matters to be submitted to the Board of Directors for discussion.

The Company has the Nomination and Compensation Committee, which holds a meeting as necessary, as a consultative body to the Board of Directors for enhancing the objectivity and independence of the functions of the Board of Directors on matters such as nomination of the candidates for Directors and Audit & Supervisory Board Members, and decisions on compensation of Directors. The Committee consists of four members, the majority of which being three Independent Outside Directors, and the chairperson be appointed from the Independent Outside Directors.

The Management Committee holds meetings twice a month, in principle, as a consultative body to the Representative Director, President and CEO for the decision making for important business matters, based on the basic policy determined by the Board of Directors.

In addition, the Executive Committee holds a meeting once a month, in principle, for the purpose of appropriately sharing among the Directors and Audit & Supervisory Board Members, including the Outside Directors and the Outside Audit & Supervisory Board Members, the status of the execution of business and material matters relating to the execution of business.
Sumitomo Dainippon Pharma has appointed five Audit & Supervisory Board members, three of whom are outside members. The Audit & Supervisory Board, composed of all the Audit & Supervisory Board members, determines audit policy, task allocation among members and other matters. In line with these matters, each member works to create an environment for greater audit effectiveness, including regular meetings with the representative directors, proactive reporting from and discussions with the other directors and employees, cooperation with the accounting auditor and the Internal Auditing Department, and furthermore, cooperation among all parties involved in auditing. In addition, members attend key business meetings including those of the Board of Directors to confirm the legality and appropriateness of management decisions by the directors and proactively audit the operational status of the internal control system through measures including receiving reports from directors and employees on the status of task execution, requesting explanation as necessary and viewing significant approval forms and other documents. The dedicated staff has been established for the Audit & Supervisory Board members to raise the effectiveness of their audits and to smoothly accomplish auditing tasks.

Accounting audits are handled by KPMG AZSA LLC, based on an audit agreement. Internal audits are carried out by the Internal Auditing Department, which reports directly to the President of Sumitomo Dainippon Pharma. The basic elements for achieving the objectives of internal control, including subsidiaries, are audited from a fair and independent standpoint.

The Board of Directors of Sumitomo Dainippon Pharma passed a resolution on the basic policies for the development of a system to ensure appropriate business operation. The status of implementation efforts pursuant to the basic policies for each year is reported based on the Companies Act at the Board of Directors meeting held in the last month of the fiscal year and the basic policies are revised as necessary to improve the system.
Business Units 1

Pharmaceuticals

The Sumitomo Dainippon Pharma Group sets the pharmaceutical business, in order to deliver innovative and useful pharmaceuticals to people worldwide as well as in Japan we make every effort in applying advanced R&D to all of our new pharmaceuticals. We advance the R&D for continuously creating new pharmaceuticals based on global development, and expand the pharmaceuticals business in Japan and worldwide.

Japan

Information provision activities

New drugs are delivered to patients after passing a long process that includes basic research, clinical studies and review by the government for regulatory approvals. Even after drug products are launched and used by a large number of patients, safety and efficacy are continually checked resulting in safe and secure, useful pharmaceuticals. It is only after proper usage has been established based on safety and efficacy information that the pharmaceuticals can fulfill their desired function of contributing effectively to human health requirements.

At Sumitomo Dainippon Pharma, we use our MR (Medical Representatives) to provide all of the requisite highly specialized information to personnel engaged in medical care. Our aim is to improve the confidence of medical personnel in Sumitomo Dainippon Pharma and to contribute via our daily MR activities to the betterment of healthcare and fuller lives of patients.

In Japan, we are progressing sales activities primarily in the Psychiatry & Neurology, Cardiovascular/Diabetes, and Speciality areas.

In the Psychiatry & Neurology area, we have therapeutic drugs for Parkinson’s disease and schizophrenia and we aim to contribute to the treatment of psychiatric and neurological diseases as a medical partner.

In the Cardiovascular/Diabetes area, we offer several products which have different mechanisms of action for hypertension and type 2 diabetes in order to respond to a wide range of medical needs. In addition, in the Speciality area (those with high unmet medical needs where intensive specialization is required), we contribute to the fields of Anderson-Fabry disease, systemic fungal infection, and pruritus in chronic liver disease.

Focus marketing areas

Products lineup

<table>
<thead>
<tr>
<th>Major pharmaceutical products</th>
<th>Therapeutic indication</th>
</tr>
</thead>
<tbody>
<tr>
<td>TRERIEF®</td>
<td>Therapeutic agent for Parkinson’s disease</td>
</tr>
<tr>
<td>LONASEN®</td>
<td>Atypical antipsychotic</td>
</tr>
<tr>
<td>AIMIX®</td>
<td>Therapeutic agent for hypertension</td>
</tr>
<tr>
<td>AVAPRO®</td>
<td>Therapeutic agent for hypertension</td>
</tr>
<tr>
<td>Trulicity®</td>
<td>GLP-1 receptor agonist</td>
</tr>
<tr>
<td>SUREPOST®</td>
<td>Rapid-acting insulin secretagogue</td>
</tr>
<tr>
<td>METGLUCO®</td>
<td>Biguanide oral hypoglycemic drug</td>
</tr>
<tr>
<td>REPLAGAL®</td>
<td>Anderson-Fabry disease drug</td>
</tr>
<tr>
<td>AmBisome®</td>
<td>Therapeutic agent for systemic fungal infection</td>
</tr>
<tr>
<td>REMITCH®</td>
<td>Therapeutic agent for pruritus</td>
</tr>
<tr>
<td>MIRIPLA®</td>
<td>Therapeutic agent for hepatocellular carcinoma</td>
</tr>
</tbody>
</table>

✽ Marketed by Torii Pharmaceutical Co., Ltd. Promoted for indication “pruritus in chronic liver disease patients” by Sumitomo Dainippon Pharma Co., Ltd.
Business Units 2

Aiming for the continuous creation of new drugs

At the Sumitomo Dainippon Pharma Group, we position the Psychiatry & Neurology and Oncology areas, both of which have high unmet medical needs, as our focus therapeutic areas where we are targeting the creation of innovative pharmaceuticals.

In the Psychiatry & Neurology areas, the Sumitomo Dainippon Pharma Group focuses on the improvement of current treatments that do not sufficiently result in adequate symptom relief, as well as the treatment of patients who do not respond enough to existing medicines, and promote research and development of therapeutic agents in schizophrenia, depression, Alzheimer’s disease, and other disorders. In the Oncology area, under the global R&D system established by Boston Biomedical, Tolero Pharmaceuticals, and the DSP Cancer Institute, the Sumitomo Dainippon Pharma Group aims to lead the world in the cancer stem cell and hematologic malignancies, and continually create innovative products. In addition, the Sumitomo Dainippon Pharma Group will apply leading-edge science, such as iPS cells to drug discovery, while strengthening activities in regenerative medicines and cell therapy to develop therapeutics for refractory diseases.

In the initial research stage, the Sumitomo Dainippon Pharma Group is working to apply leading-edge scientific technologies, including supercomputer-assisted in silico methods and iPS cells, to drug discovery and regenerative medicine/cell therapy. The Sumitomo Dainippon Pharma Group also proactively seeks external research collaboration with universities and other research institutions throughout the globe. During FY2016, the second term of the joint research project with Kyoto University (DSK Project), which aims to discover innovative anti-cancer drugs, was launched. Meanwhile, under the Partnership to Realize Innovative Seeds and Medicines (PRISM) framework, which is an open innovation program launched in FY2015 whereby research institutions and researchers in Japan are invited to submit ideas that meet the Sumitomo Dainippon Pharma’s drug discovery research needs, joint research agreements were signed on multiple ideas during FY2016.

In the latter research stage and the development stage, a global perspective is taken to optimize the project portfolio for the Sumitomo Dainippon Pharma Group’s focus therapeutic areas and newer fields, as well as other areas. The Sumitomo Dainippon Pharma Group is also committed to product life cycle management and drug repositioning by developing dosage forms in ways that maximize product value.

The Sumitomo Dainippon Pharma Group is enhancing its presence in Oncology with the aim of making it a future core business area in addition to Psychiatry & Neurology. In April 2012, Sumitomo Dainippon Pharma acquired U.S. biotechnology company Boston Biomedical, Inc., which specializes in the area of Oncology. With this acquisition, we made a full-scale start on our global expansion in Oncology.

With the aim to create innovative new drugs, in September 2012 we established the DSP Cancer Institute in Japan (Location: Osaka Research Center) as an organization independent from the Drug Research Division under the direct control of the president. In February 2013 we set up a new base in Cambridge, Massachusetts, U.S. in order to expand the scale of research activities of Boston Biomedical. In January 2017, we acquired Tolero Pharmaceuticals, Inc., which generates unique compounds expecting potential options for hematologic malignancies, and expand our global cancer research and development system.

Full-scale participation in oncology
Business Units 3

Setting global development as a basic strategy

The Sumitomo Dainippon Pharma Group has R&D bases in the three regions of Japan, the U.S. and China that engage in collaborative activities under the management of the Chief Scientific Officer (CSO). The Sumitomo Dainippon Pharma Group established the Global Business Strategy Committee (GBSC) in April 2012 to make efficient the R & D management function of CSO. GBSC works to optimize the Sumitomo Dainippon Pharma Group’s overall portfolio with a global perspective by discussing issues including global business strategy, licensing proposals, and strategic prioritization and resource allocation for R&D, in addition, discusses the promotion of projects in early development stages and other issues with a global perspective. As for clinical development, the Sumitomo Dainippon Pharma Group will strengthen the global seamless management and promote development in a speedier and more efficient manner under the Head of Global Clinical Development.

Pharmaceuticals production

Recognizing that pharmaceuticals play a vital role in maintaining human health, we are dedicated to assuring that all pharmaceutical products have their designed quality. Manufacturing and quality control of pharmaceuticals are required to be carried out strictly in accordance with Good Manufacturing Practice (GMP) standards in each country. The pharmaceuticals manufactured by the Sumitomo Dainippon Pharma Group are exported around the world after obtaining approval from the regulatory authorities of importing nations, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and Australia’s Therapeutic Goods Administration (TGA). Therefore, operating standards in the Sumitomo Dainippon Pharma Group are consistent with the GMP standards of Europe and the United States. Furthermore, we have established a high level of facility design and a quality assurance system to meet strict quality standards at the global level, including audits by overseas partner companies and the guidelines of the International Conference on Harmonisation (ICH), which deliberates the harmonization of EU, U.S. and Japanese pharmaceutical regulations.

Global standards for quality assurance are expected to become increasingly rigorous. The Sumitomo Dainippon Pharma Group is therefore making proactive investments in manufacturing facilities — including a new solid dosage form facility and a restricted access barrier system (RABS) that increases the level of sterility assurance — to meet future standards. Our manufacturing, quality assurance and other related divisions will work in concert to continue to provide pharmaceuticals of the highest quality.

Manufacturing bases

- **Suzuka Plant**
  As a production site focusing on efficiency, Suzuka Plant maintains integrated pharmaceutical manufacturing facilities at which a full range of operations are conducted, from production of active pharmaceutical ingredients and finished products to packaging.

- **Ibaraki Plant**
  Since Technology Research and Development Division’s Formulation Technology Research Department is located in the Ibaraki Plant, from manufacturing technology research to manufacturing and quality control practice, as an R&D-driven pharmaceuticals plant able to flexibly accommodate new products and technologies, this plant produces drugs in dosage forms, including solid dosages, powders, tablets, capsules and injections.

- **Ehime Plant**
  Ehime Plant manufactures sterile injectables under strict quality control system.

- **Oita Plant**
  Oita Plant is our core facility for active pharmaceutical ingredients. Operating 24 hours a day, 365 days a year, the plant manufactures active ingredients.
Sumitomo Dainippon Pharma acquired U.S. company, Sepracor Inc. (Current Sunovion Pharmaceuticals Inc.) in October 2009, and then merged it with our subsidiary Dainippon Sumitomo Pharma America Inc. in April 2010 and changed the company name to Sunovion Pharmaceuticals Inc. (Sunovion). Currently, Sunovion plays a major role in the North American business of the Sumitomo Dainippon Pharma Group.

Sunovion aims to maximize earnings from LATUDA® (launched in February 2011) in addition to optimizing the field force structure for existing products.

**Corporate Profile**

<table>
<thead>
<tr>
<th>Established</th>
<th>January 1984</th>
</tr>
</thead>
<tbody>
<tr>
<td>Head office location</td>
<td>Marlborough, Massachusetts, U.S.A.</td>
</tr>
<tr>
<td>Recent achievements</td>
<td>197.9 billion yen (FY 2016)</td>
</tr>
</tbody>
</table>

**Product lineup**

<table>
<thead>
<tr>
<th>Major pharmaceutical products</th>
<th>Therapeutic indication</th>
</tr>
</thead>
<tbody>
<tr>
<td>LATUDA®</td>
<td>Atypical antipsychotic</td>
</tr>
<tr>
<td>APTIOM®</td>
<td>Antiepileptic</td>
</tr>
<tr>
<td>UTIBRON™ NEOHALER®</td>
<td>Long-acting muscarinic antagonist/Long-acting beta agonist</td>
</tr>
<tr>
<td>SEEEBRI™ NEOHALER®</td>
<td>Long-acting muscarinic antagonist</td>
</tr>
<tr>
<td>ARCAPTA® NEOHALER®</td>
<td>Long-acting beta agonist</td>
</tr>
<tr>
<td>BROVANA®</td>
<td>Long-acting beta agonist</td>
</tr>
<tr>
<td>LUNESTA®</td>
<td>Sedative hypnotic</td>
</tr>
<tr>
<td>XOPENEX HFA®</td>
<td>Short-acting beta agonist</td>
</tr>
</tbody>
</table>
China

The Sumitomo Dainippon Pharma Group is positively deploying business in China by setting it as an important growing market. In this market, our subsidiary Sumitomo Pharmaceuticals (Suzhou) Co., Ltd. is in charge of operations, from the production to sale of four products locally including MEPEM®. The plant at Sumitomo Pharmaceuticals (Suzhou) Co., Ltd. currently packages our products for sale in the local market. Fully integrated production, from formulation to packaging, is currently being prepared. By bringing new products in addition to existing products to the market, we are aiming for steady growth.

Corporate Profile

<table>
<thead>
<tr>
<th>Established</th>
<th>December 2003</th>
</tr>
</thead>
<tbody>
<tr>
<td>Head office location</td>
<td>Suzhou Industrial Park, Jiangsu Province, People’s Republic of China</td>
</tr>
<tr>
<td>Recent achievements</td>
<td>17.6 billion yen (FY 2016)</td>
</tr>
</tbody>
</table>

Product lineup

<table>
<thead>
<tr>
<th>Major pharmaceutical products</th>
<th>Therapeutic indication</th>
</tr>
</thead>
<tbody>
<tr>
<td>MEPEM® (Brand name in Japan: MEROPEN®)</td>
<td>Carbapenem antibiotic</td>
</tr>
<tr>
<td>ALMARL® (Brand name in Japan: Arotinolol Hydrochloride)</td>
<td>Therapeutic agent for hypertension, angina pectoris and arrhythmia</td>
</tr>
<tr>
<td>SEDIEL®</td>
<td>Serotonin-agonist antianxiety drug</td>
</tr>
<tr>
<td>GASMOTIN®</td>
<td>Gastroprokine</td>
</tr>
</tbody>
</table>

Other Products

The food ingredients and chemical product materials business is handled by Sumitomo Dainippon Pharma subsidiary DSP Gokyo Food & Chemical Co., Ltd. The animal health products business is conducted by Sumitomo Dainippon Pharma subsidiary DS Pharma Animal Health Co., Ltd. Sumitomo Dainippon Pharma subsidiary DS Pharma Biomedical Co., Ltd. conducts the diagnostics and research materials business.
**Board Members and Executive Officers**

(As of October 1, 2017)

<table>
<thead>
<tr>
<th>Post</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Representative Director, President and CEO</td>
<td>Masayo Tada</td>
</tr>
<tr>
<td>Representative Director, Executive Vice President</td>
<td>Hiroshi Nomura</td>
</tr>
<tr>
<td>Global Corporate Planning; External Affairs; Corporate Secretariat &amp; Industry Affairs; Personnel; Finance &amp; Accounting</td>
<td></td>
</tr>
<tr>
<td>Member, Board of Directors, Senior Executive Officer</td>
<td>Hitoshi Odagiri</td>
</tr>
<tr>
<td>Executive Director, Sales &amp; Marketing Division</td>
<td></td>
</tr>
<tr>
<td>Member, Board of Directors, Executive Officer</td>
<td>Toru Kimura</td>
</tr>
<tr>
<td>Senior Executive Research Director, Regenerative &amp; Cellular Medicine Office; Regenerative &amp; Cellular Medicine Kobe Center</td>
<td></td>
</tr>
<tr>
<td>Member, Board of Directors, Executive Officer</td>
<td>Nobuyuki Hara</td>
</tr>
<tr>
<td>Executive Director, Corporate Regulatory Compliance &amp; Quality Assurance Division; Regulatory Affairs; Medical Information; Medical Affairs; Drug Development Division</td>
<td></td>
</tr>
<tr>
<td>Member, Board of Directors (Outside)</td>
<td>Hidehiko Sato</td>
</tr>
<tr>
<td>Member, Board of Directors (Outside)</td>
<td>Hiroshi Sato</td>
</tr>
<tr>
<td>Audit &amp; Supervisory Board Member</td>
<td>Nobuo Takeda</td>
</tr>
<tr>
<td>Audit &amp; Supervisory Board Member</td>
<td>Yoshinori Oh-e</td>
</tr>
<tr>
<td>Audit &amp; Supervisory Board Member (Outside)</td>
<td>Harumichi Uchida</td>
</tr>
<tr>
<td>Audit &amp; Supervisory Board Member (Outside)</td>
<td>Kazuto Nishikawa</td>
</tr>
<tr>
<td>Audit &amp; Supervisory Board Member (Outside)</td>
<td>Junsuке Fujii</td>
</tr>
<tr>
<td>Senior Executive Officer, Chairman and CEO, Sunovion Pharmaceuticals Inc.</td>
<td>Nobuhiko Tamura</td>
</tr>
<tr>
<td>Senior Executive Officer, Executive Director, Manufacturing Division; Technology Research &amp; Development Division</td>
<td>Yoshiharu Ikeda</td>
</tr>
<tr>
<td>Senior Executive Officer, Global Oncology Office; Oncology Clinical Development Unit; Oncology Strategy Unit; DSP Cancer Institute; Global Head of Oncology</td>
<td>Kazuo Koshiya</td>
</tr>
<tr>
<td>Executive Officer, Senior Director, Global Corporate Planning; Legal Affairs; Intellectual Property; IT Management &amp; Digital Transformation</td>
<td>Hiroyuki Baba</td>
</tr>
<tr>
<td>Executive Officer, Director, Corporate Governance; Corporate Service Center</td>
<td>Hajime Kinuta</td>
</tr>
<tr>
<td>Executive Officer, Executive Research Director, Drug Research Division</td>
<td>Hideyuki Harada</td>
</tr>
<tr>
<td>Executive Officer, Deputy Executive Director, Sales &amp; Marketing Division</td>
<td>Mitsuyuki Taniguchi</td>
</tr>
<tr>
<td>Executive Officer, Corporate Governance (External Communications); Personnel (Diversification)</td>
<td>Atsuko Higuchi</td>
</tr>
<tr>
<td>Executive Officer, Senior Director, Global Business Development; International Business Management</td>
<td>Shigeyuki Nishinaka</td>
</tr>
<tr>
<td>Executive Officer</td>
<td>Antony Loebel</td>
</tr>
<tr>
<td>-------------------------------------------------------</td>
<td>---------------</td>
</tr>
<tr>
<td>Executive Vice President, CMO, Sunovion Pharmaceuticals Inc.; Head of Global Clinical Development for Sumitomo Dainippon Pharma Group</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Executive Officer</th>
<th>Patricia S. Andrews</th>
</tr>
</thead>
<tbody>
<tr>
<td>CEO, Boston Biomedical, Inc.</td>
<td></td>
</tr>
</tbody>
</table>
Key Facilities

- **Osaka Head Office**
  6-8, Doshomachi 2-chome, Chuo-ku, Osaka, Osaka, 541-0045, Japan
  TEL : +81-6-6203-5321
  FAX : +81-6-6202-6028

- **Tokyo Head Office**
  13-1, Kyobashi 1-chome, Chuo-ku, Tokyo, 104-8356, Japan
  TEL : +81-3-5159-2500
  FAX : +81-3-5159-2845

- **Tokyo Kyobashi Office**
  17-10, Kyobashi 1-chome, Chuo-ku, Tokyo, 104-0031, Japan

- **Regenerative & Cellular Medicine Kobe Center**
  Kobe KIMEC Center Building 5th Fl,
  5-2, Minatojimaminamimachi 1-chome, Chuo-ku, Kobe, Hyogo, 650-0047, Japan
  TEL : +81-078-306-2170
  FAX : +81-078-303-4040

- **Suzuka Plant**
  1450 Yasuzuka-cho, Suzuka, Mie, 513-0818, Japan
  TEL : +81-59-382-8951
  FAX : +81-59-382-4505

- **Ibaraki Plant**
  3-45, Kurakakiuchi 1-chome, Ibaraki, Osaka, 567-0878, Japan
  TEL : +81-72-627-8112
  FAX : +81-72-627-8110

- **Ehime Plant**
  5-1, Sobiraki-cho, Niihama, Ehime, 792-0001, Japan
  TEL : +81-897-37-7600
  FAX : +81-897-35-2534

- **Oita Plant**
  2200 Oaza Tsurusaki, Oita, Oita, 870-0106, Japan
  TEL : +81-97-523-1177
  FAX : +81-97-523-1121

- **Central Research Laboratories**
  33-94, Enoki-cho, Suita, Osaka, 564-0053, Japan
  TEL : +81-6-6337-5876
  FAX : +81-6-6337-6538

- **Osaka Research Center**
  1-98, Kasugade-naka 3-chome, Konohana-ku, Osaka, Osaka, 554-0022, Japan
  TEL : +81-6-6466-5183
  FAX : +81-6-6466-5483

- **Tokyo Distribution Center**
  37-1, Kitatsuji, Kazo, Saitama, 347-0023, Japan
  TEL : +81-480-65-2240
  FAX : +81-480-65-2986

- **Kobe Distribution Center**
  16-2, Yasakadai 3-chome, Suma-ku, Kobe, Hyogo, 654-0161, Japan
  TEL : +81-78-796-0150
  FAX : +81-78-796-0154

Sumitomo Dainippon Pharma Co., Ltd.
Major Consolidated Subsidiaries

Main Subsidiaries

● DSP Gokyo Food & Chemical Co., Ltd.
  20F, HERBIS OSAKA, 5-25, Umeda 2-chome, Kita-ku, Osaka, Osaka 530-0001, Japan
  TEL : +81-6-7177-6874
  FAX : +81-6-6453-0941

● DS Pharma Animal Health Co., Ltd.
  10F, METLIFE Honmachi Square, 5-7, Honmachi 2-chome, Chuo-ku, Osaka, Osaka 541-0053, Japan
  TEL : +81-6-4705-8180
  FAX : +81-6-4705-8060

● DS Pharma Biomedical Co., Ltd.
  33-94, Enoki-cho, Suita, Osaka 564-0053, Japan
  TEL : +81-6-6337-5940
  FAX : +81-6-6337-5997

Overseas Local Subsidiaries

● Sumitomo Dainippon Pharma America, Inc.
  1209 Orange Street, Wilmington, County of New Castle, DE 19801

● Sunovion Pharmaceuticals Inc.
  84 Waterford Drive Marlborough, MA 01752
  TEL : +1-508-481-6700
  FAX : +1-508-481-7683

● Boston Biomedical, Inc.
  640 Memorial Drive, Cambridge, MA 02139
  TEL : +1-617-674-6800
  FAX : +1-617-674-8661

● Tolero Pharmaceuticals, Inc.
  3900 N Traverse Mountain Blvd, Suite 100 Lehi, UT 84043
  TEL : +1-801-285-6003
  FAX : +1-801-746-3314

● Sumitomo Pharmaceuticals (Suzhou) Co., Ltd.
  No.115 QingQiu Street, SIP, Jiangsu Province, 215126 China
  TEL : +86-512-6283-1082
  FAX : +86-512-6283-1083

● Sunovion Pharmaceuticals Europe Ltd.
  First Floor, Southside, 97-105 Victoria Street, London SW1E 6QT, U.K.
  TEL : +44- (0) 20-7821-2840
  FAX : +44- (0) 20-7821-2841

● Sunovion Pharmaceuticals Asia Pacific Pte. Ltd.
  150 Beach Road, #14-03 Gateway West, Singapore 189720